GSK vaccine proves effective in fighting malaria
The quest for the world’s first malaria vaccine appears to have taken a big step: A study in Africa shows experimental shots of a vaccine developed by GlaxoSmithKline (NYSE: GSK) cut the risk of disease in young children by half. The initial results from a final stage of vaccine testing were released Tuesday, and the vaccine’s developers called it a milestone in helping to tame one of the world’s most devastating killers. “These data bring us to the cusp of having the world’s first malaria vaccine, which has the potential to significantly improve the outlook for children living in...
Read More